Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Vantage logo

Abbvie takes its Treg cue

The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.